Brady’s founder steps down after 25 years; to boost activity with Cambridge start-ups

Brady plc, provider of trading, risk management and settlement software to the metals and commodities sectors, said Chief Technology Officer Robert Brady will become a non-executive director of the company he founded 25 years ago in September.

Dr. Brady will remain a major shareholder in the Cambridge-based company.

Dr. Brady said: "The company is ideally positioned to capitalise on the current global opportunities. The new management team shares our existing values - to understand the market, understand the client and provide the best solution through appropriate technology - and is taking us forward into a new phase of international growth.

"My position as a non-executive director will continue to keep me involved with the company and the reduced role will give me more time to devote to my passion for entrepreneurship in the UK. Specifically, I will be increasing my activity in the Cambridge area with non-competing technology start-ups."

Brady CEO Gavin Lavelle said: "Robert has taken a one man consultancy and built the business into a strong public company, which is now a leading provider of trading and risk management technology solutions to the metals and commodity markets.

"This is a tremendous achievement by Robert and I am particularly pleased that we will continue to benefit from his continued participation and support in the future growth of the company. I would also like to personally thank Robert for his unstinting support since I joined the company in 2007."

Dr. Brady began in 1985 developing pricing algorithms for the FX market, and by 1989 had expanded to include swaps, interest rate derivatives and metal derivative risk management solutions.

Within ten years the company had started to make its mark in the metals and commodities markets. With the increase in capitalisation resulting from its UK AIM listing in 2004, Dr. Brady and his Board colleagues set about growing the company.

2007 saw a step change in this growth with a number of senior new hires joining the Board, including CEO Gavin Lavelle

Brady plc is currently valued at around £13.3m.

 



Previous articles
Tech Report: Cambridge brain waves open communication for the severely paralysed
News snippets: Prelude ellicits some interest; Cybit signs up £1.2m new business
Listed Silicon Fenners show cause for celebration, and concern
Clinical Cell Culture's CEO leaves after strategic review; costs cut
NXT soars as Toyota fits flat panel speakers into new models
Dialight reports 23% growth in sales in 08, pre-tax profit up 26%, helped by strong dollar
Bango raises £3m in share placing to accelerate payments to content providers
BioProgress lives up to its name as it goes forward in 2006
Stem Cell Sciences’ losses widen in 07; sees marketing delivering revenue growth in 08
CSR bolsters technology as Bluetooth reaches beyond cellular applications
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • Cambridge Biostability


Shevanti Sen
R&D Director


Cambridge Biostability Ltd is a privately held company founded in 1998 with a combination of investor funding and project financing. It has a portfolio of patents and is entering into a number of agreements to licence and provide outsourced production of thermo-stable liquid vaccines and drugs. Development

[Cambridge Biostability's profile]


Top20 Index




Currently: 127.57

Personal Loans
All About Loans offers you advice and information all about loans. Talk to us about finding the best possible Perosnal loan.

Compare Mortgages Online
In order to choose the best deal for your situation, compare mortgages online.

Marcus Evans
See what other companies thought of this top company's excellent training courses!

Marcus Evans Scam
Marcus Evans Scam conferences teach you how to implement an ethical culture among your employees.

Ferro Chrome
Would you like to know more about the ferro chrome industry. Check out the IFML website.